A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma

Yung Hung Luo, Pei Chun Tseng, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng, Yuh Min Chen

研究成果: 雜誌貢獻回顧型文獻

4 引文 (Scopus)

摘要

BACKGROUND: The use of liquid tissue, such as circulating cells, to predict treatment response is attracting more attention. OBJECTIVE: The aim of this study was to evaluate association between circulating markers and treatment response. METHODS: One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry. RESULTS: The progression-free survival (PFS) was significantly longer in patients with low CEC, low EPC, and low CSC counts than in those with high cell counts (p < 0.001, 0.041, and 0.001, respectively). Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048), and there was a tendency for EGFR mutation-negative patients with high IL-6 level to have worse overall survival (p = 0.051). CONCLUSIONS: CECs, EPCs, CSCs, and mutant pEGFR are useful predictive biomarkers of EGFR-TKI treatment efficacy. IL-6 may predict prognosis in advanced lung cancer.
原文英語
頁(從 - 到)19-29
頁數11
期刊Cancer Biomarkers
16
發行號1
DOIs
出版狀態已發佈 - 一月 18 2016

指紋

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Neoplastic Stem Cells
Prospective Studies
Interleukin-6
Endothelial Cells
Cell Count
Mutation
Therapeutics
Interleukin-8
Disease-Free Survival
Lung Neoplasms
Flow Cytometry
Multivariate Analysis
Biomarkers
Survival
Adenocarcinoma of lung
Endothelial Progenitor Cells
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

引用此文

A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. / Luo, Yung Hung; Tseng, Pei Chun; Lee, Yu Chin; Perng, Reury Perng; Whang-Peng, Jacqueline; Chen, Yuh Min.

於: Cancer Biomarkers, 卷 16, 編號 1, 18.01.2016, p. 19-29.

研究成果: 雜誌貢獻回顧型文獻

@article{821fe69c25c3449db520027384ff5f82,
title = "A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma",
abstract = "BACKGROUND: The use of liquid tissue, such as circulating cells, to predict treatment response is attracting more attention. OBJECTIVE: The aim of this study was to evaluate association between circulating markers and treatment response. METHODS: One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry. RESULTS: The progression-free survival (PFS) was significantly longer in patients with low CEC, low EPC, and low CSC counts than in those with high cell counts (p < 0.001, 0.041, and 0.001, respectively). Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048), and there was a tendency for EGFR mutation-negative patients with high IL-6 level to have worse overall survival (p = 0.051). CONCLUSIONS: CECs, EPCs, CSCs, and mutant pEGFR are useful predictive biomarkers of EGFR-TKI treatment efficacy. IL-6 may predict prognosis in advanced lung cancer.",
keywords = "Adenocarcinoma, Cancer stem cells, Circulating endothelial cells, Cytokines, Endothelial progenitor cells, Epidermal growth factor receptor (EGFR)",
author = "Luo, {Yung Hung} and Tseng, {Pei Chun} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng and Chen, {Yuh Min}",
year = "2016",
month = "1",
day = "18",
doi = "10.3233/CBM-150537",
language = "English",
volume = "16",
pages = "19--29",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma

AU - Luo, Yung Hung

AU - Tseng, Pei Chun

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

AU - Chen, Yuh Min

PY - 2016/1/18

Y1 - 2016/1/18

N2 - BACKGROUND: The use of liquid tissue, such as circulating cells, to predict treatment response is attracting more attention. OBJECTIVE: The aim of this study was to evaluate association between circulating markers and treatment response. METHODS: One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry. RESULTS: The progression-free survival (PFS) was significantly longer in patients with low CEC, low EPC, and low CSC counts than in those with high cell counts (p < 0.001, 0.041, and 0.001, respectively). Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048), and there was a tendency for EGFR mutation-negative patients with high IL-6 level to have worse overall survival (p = 0.051). CONCLUSIONS: CECs, EPCs, CSCs, and mutant pEGFR are useful predictive biomarkers of EGFR-TKI treatment efficacy. IL-6 may predict prognosis in advanced lung cancer.

AB - BACKGROUND: The use of liquid tissue, such as circulating cells, to predict treatment response is attracting more attention. OBJECTIVE: The aim of this study was to evaluate association between circulating markers and treatment response. METHODS: One hundred and twelve advanced pulmonary adenocarcinoma patients who were going to receive epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were included. Tumor tissue and plasma specimens were collected before treatment and analyzed for EGFR mutation and plasma IL-6 and IL-8. Pre-treatment peripheral blood CD146+/CD3- cells (as circulating endothelial cells, CECs), CD34+/CD45- cells (as endothelial progenitor cells, EPCs), and CD133+ cells (as cancer stem cells, CSCs) were measured with flow cytometry. RESULTS: The progression-free survival (PFS) was significantly longer in patients with low CEC, low EPC, and low CSC counts than in those with high cell counts (p < 0.001, 0.041, and 0.001, respectively). Multivariate analysis showed that mutant plasma EGFR (pEGFR) was a poor prognostic factor in EGFR-mutated patients (p = 0.048), and there was a tendency for EGFR mutation-negative patients with high IL-6 level to have worse overall survival (p = 0.051). CONCLUSIONS: CECs, EPCs, CSCs, and mutant pEGFR are useful predictive biomarkers of EGFR-TKI treatment efficacy. IL-6 may predict prognosis in advanced lung cancer.

KW - Adenocarcinoma

KW - Cancer stem cells

KW - Circulating endothelial cells

KW - Cytokines

KW - Endothelial progenitor cells

KW - Epidermal growth factor receptor (EGFR)

UR - http://www.scopus.com/inward/record.url?scp=84956788032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956788032&partnerID=8YFLogxK

U2 - 10.3233/CBM-150537

DO - 10.3233/CBM-150537

M3 - Review article

C2 - 26484608

AN - SCOPUS:84956788032

VL - 16

SP - 19

EP - 29

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 1

ER -